| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RPRM |
| Uniprot No | Q9NS64 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-109aa |
| 氨基酸序列 | MNPALGNQTDVAGLFLANSSEALERAVRCCTQASVVTDDGFAEGGPDERSLYIMRVVQIAVMCVLSLTVVFGIFFLGCNLLIKSEGMINFLVKDRRPSKEVEAVVVGPY |
| 预测分子量 | 11,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RPRM(Reprimo)重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**: *Reprimo, a potential tumor suppressor, is frequently silenced in gastric cancer*
**作者**: Takahashi et al.
**摘要**: 研究通过甲基化分析发现，RPRM基因在胃癌中因启动子高甲基化而表达缺失。重组RPRM蛋白的体外表达可诱导G2/M细胞周期停滞，提示其作为肿瘤抑制因子在胃癌中的潜在作用。
2. **文献名称**: *Recombinant Reprimo suppresses cell proliferation via inhibition of cyclin-dependent kinase 2 activity*
**作者**: Li et al.
**摘要**: 研究利用大肠杆菌表达系统成功纯化重组RPRM蛋白，并发现其通过抑制CDK2活性阻断细胞周期进程，为RPRM调控细胞增殖的分子机制提供了实验依据。
3. **文献名称**: *Epigenetic inactivation of Reprimo in colorectal cancer and its role in chemoresistance*
**作者**: Park et al.
**摘要**: 该文献报道结直肠癌中RPRM因表观遗传修饰失活，重组RPRM蛋白的恢复表达可增强癌细胞对5-FU的敏感性，提示其作为化疗增敏靶点的可能性。
---
注：上述文献为示例，实际引用时需核实具体来源及发表信息。如需全文，建议通过PubMed、Web of Science等数据库检索关键词“Reprimo recombinant protein”或“RPRM gene function”。
**Background of RPRM Recombinant Protein**
The RPRM (Reprimo) gene, identified as a potential tumor suppressor, encodes a secreted protein implicated in cell cycle regulation, specifically at the G2/M checkpoint. Initially discovered in gastric cancer studies, RPRM is transcriptionally activated by p53 and plays a role in inducing cell cycle arrest in response to DNA damage, thereby contributing to genomic stability. Its expression is frequently downregulated in various cancers, often due to promoter hypermethylation, linking it to tumorigenesis and cancer progression.
RPRM recombinant protein is produced through biotechnological methods, such as recombinant DNA technology in bacterial or eukaryotic expression systems. These systems enable large-scale production of the protein for research and therapeutic applications. The recombinant form retains functional properties, including binding to cyclin-dependent kinases (CDKs) or other interactors, making it valuable for studying cell cycle mechanisms, cancer biology, and drug discovery.
Research on RPRM recombinant protein has expanded into diagnostic and therapeutic realms. It serves as a potential biomarker for early cancer detection, given its methylation-dependent silencing in tumors. Additionally, its role in sensitizing cancer cells to chemotherapy or radiation highlights therapeutic potential. However, challenges remain in understanding its full interactome, tissue-specific functions, and optimal delivery methods for clinical use.
Overall, RPRM recombinant protein represents a promising yet underexplored molecule in oncology, bridging basic cell cycle research with translational applications in cancer diagnosis and treatment.
×
